Sex, Lies, and the HPV Vaccine
By Julia Scirrotto
Photo Credit: Jeff Westbrook
At last, Gardasil promised to quiet the paranoia by protecting against four of the nastiest HPV strains (two responsible for 70 percent of all cervical cancers and two that cause 90 percent of all genital warts) — but there was a catch. The vaccine works best before a person is exposed to the virus, and since most of us will acquire HPV at some point in our lives, that means it works best in virgins. Plus, because the vaccine was originally studied in girls and women ages 9 to 26, the FDA approved it only for that demographic. Many under-26 sex-havers counted themselves out (or were dissuaded by their doctors) — to say nothing of the 27-plus set that was automatically disqualified. I was lucky to still be 26 when I sought out the vaccine — meaning, among other things, that my insurance company would reimburse me the $494.85. But after I completed my last dose, I had lingering questions about the age cutoff and this whole “works best in virgins” business (I know that public-health recommendations need limits, but the “fallen woman” implications stung a bit). So, more than a little frustrated, I called up the experts who have studied HPV for some answers.
For starters, I learned that there’s no biological expiration date that magically arrives on a woman’s 27th birthday. As Dr. Thomas Herzog of Columbia University Medical Center explained, 26 was the age cap in the original studies because researchers sensibly wanted to focus on the group with the highest rate of HPV infection rather than dilute the findings. What’s more, all three doctors I talked to have administered the vaccine to women over 26. “A 27- or 28-year-old who wants to be vaccinated, who understands the limitations of our knowledge in that age group — I’m willing to vaccinate her,” added Dr. Kevin Holcomb of Weill-Cornell Medical Center.
In fact, women who have had previous HPV infections (even those that may have developed into cervical precancer) can see some benefit from the vaccine. Holcomb put it this way: “Somebody who’s had an abnormal Pap — you don’t know exactly which HPV types she’s had. I would recommend that you do vaccinate her, with the caveat that she understands it’s not going to change the HPV infection she may already have. But it is extremely unlikely that she would have already been exposed to all four types of HPV [prevented by] Gardasil.” So much for the fallen-woman disqualifier. Holcomb’s approach seemed to back up what I’d felt in my gut all along: My peers and I should do everything we can to protect ourselves (including regular Paps, vaccinated or not), even if we did end up on the tail end of this breakthrough.
Fortunately, the age cap of 26 may soon be a thing of the past. Last November, Merck released data showing Gardasil to be highly effective in women up to 45, which could convince the FDA to extend approval to women over 26. And another version of the vaccine (GlaxoSmithKline’s Cervarix, which protects against the same two cancer-causing HPV strains as Gardasil) is expected to win FDA approval early this year, possibly for women as old as 55. Having two versions on the market will most likely bring prices down and eliminate some of the barriers to access — a positive sign that lunch-hour syringe refrigeration and the stick-and-run treatment from reluctant OB/GYNs could be on the way out.
In the meantime, I’m encouraging anyone who will listen to get the vaccine, however infuriating the red tape might be. Because, contrary to what my gynecologist may believe, we don’t have to be “on our own” when it comes to HPV protection. As for me, I’m glad I pushed the issue when
I did. My boyfriend and I broke up shortly before my last injection.
I would’ve told my doctor about it, but she was in a hurry.
post a comment